Search results for "Positron"

showing 10 items of 1346 documents

Bone metastasis of a breast cancer detected by 3'-deoxy-3'-18F-fluorothymidine PET/CT

2008

International audience

Adultmedicine.medical_specialtyBone NeoplasmsBreast NeoplasmsDocetaxel[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicine030204 cardiovascular system & hematology01 natural sciencesBone and Bones[SDV.IB.MN] Life Sciences [q-bio]/Bioengineering/Nuclear medicine[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicine03 medical and health sciences0302 clinical medicineBreast cancermedicineHumansRadiology Nuclear Medicine and imagingComputingMilieux_MISCELLANEOUSEpirubicinPET-CT010405 organic chemistrybusiness.industryBone metastasisGeneral Medicinemedicine.diseaseDideoxynucleosides3. Good health0104 chemical sciences18f fluorothymidineTreatment OutcomePositron-Emission TomographyFemaleTaxoidsRadiologybusinessTomography X-Ray Computed
researchProduct

SPECT Bone scintigraphy of benign and malignant lesions of the spine

1989

70 patients were examined with planar and SPECT bone scintigraphy. SPECT proved to be superior over planar bone scanning for imaging of traumatic, inflammatory, and malignant bone lesions. SPECT provides three-dimensional information and, therefore, delineates the exact location and extension of lesions. It also has a higher sensitivity than planar bone scintigraphy. The three-dimensional bone scan generates complementary diagnostic information which often facilitates an adequate therapy protocol.

Adultmedicine.medical_specialtyDiagnostic informationHumansMedicineRachisTomography Emission-Computed Single-PhotonSpinal Neoplasmsmedicine.diagnostic_testbusiness.industryGeneral MedicineSpineVertebraBone scanningmedicine.anatomical_structureBone scintigraphyBone lesionPositron emission tomographyFemaleSpinal DiseasesSurgeryNeurology (clinical)NeurosurgeryRadiologybusinessNuclear medicineNeurosurgical Review
researchProduct

Sympathetic activity at rest and motor brain areas: FDG-PET study.

2008

Although recent studies identified brain areas which are involved in short term activation of the sympathetic nervous system, little is known about brain mechanisms which generate the individual variability of basal autonomic activity. In this fluorodeoxyglucose positron emission tomography study (FDG-PET), we aimed to identify brain regions, which covary with function parameters of the autonomic nervous system at rest. Therefore, FDG-PET (Siemens, Germany) was performed twice in 14 healthy resting subjects (7 m, 7 f; mean age 29.5 years) while different parameters of autonomic function were assessed simultaneously: Blood pressure, heart rate, power spectra of heart rate variability (HF/LF …

Adultmedicine.medical_specialtySympathetic nervous systemSympathetic Nervous SystemRestBlood PressureCellular and Molecular NeuroscienceMuscle toneNorepinephrineFluorodeoxyglucose F18Heart RateInternal medicineHeart ratemedicineHeart rate variabilityHumansAttentionChromatography High Pressure LiquidEndocrine and Autonomic SystemsBrainAutonomic nervous systemmedicine.anatomical_structureEndocrinologyBlood pressureGlucosePositron-Emission TomographyNeurology (clinical)Primary motor cortexRadiopharmaceuticalsPsychologyMotor cortexAutonomic neuroscience : basicclinical
researchProduct

Gaussian Mixture Models and Model Selection for [18F] Fluorodeoxyglucose Positron Emission Tomography Classification in Alzheimer’s Disease

2015

We present a method to discover discriminative brain metabolism patterns in [18F] fluorodeoxyglucose positron emission tomography (PET) scans, facilitating the clinical diagnosis of Alzheimer's disease. In the work, the term "pattern" stands for a certain brain region that characterizes a target group of patients and can be used for a classification as well as interpretation purposes. Thus, it can be understood as a so-called "region of interest (ROI)". In the literature, an ROI is often found by a given brain atlas that defines a number of brain regions, which corresponds to an anatomical approach. The present work introduces a semi-data-driven approach that is based on learning the charac…

Aged 80 and overMaleMILD COGNITIVE IMPAIRMENTScience & TechnologyPREDICTIONGeneral Science & TechnologyNormal DistributionBrainModels TheoreticalDIAGNOSISSensitivity and SpecificityMultidisciplinary SciencesPETAlzheimer DiseaseFluorodeoxyglucose F18Positron-Emission TomographyMD MultidisciplinaryHumansScience & Technology - Other TopicsFemaleRadiopharmaceuticalsResearch ArticleAged
researchProduct

Prosthetic joint infection caused by Mycobacterium avium complex.

2019

Aged 80 and overMaleProsthesis-Related Infectionsbiologybusiness.industryProsthetic joint infectionGeneral Medicinebiology.organism_classificationMycobacterium avium ComplexMicrobiologyFatal OutcomePositron-Emission TomographyMedicineHumansMycobacterium avium complexHip ProsthesisbusinessMycobacterium avium-intracellulare InfectionQJM : monthly journal of the Association of Physicians
researchProduct

Immunological and immunogenetic markers in sporadic Alzheimer’s disease

2006

Background: Common polymorphisms of genes controlling inflammation-modulating cytokines and acute-phase proteins which play important roles in the pathogenesis of Alzheimer''s disease (AD) have been shown to be associated with AD. Aims: The immunological and immunogenetic markers potentially useful for the AD risk evaluation and diagnosis are briefly reviewed. Conclusion: The state-of-the-art of immunological and immunogenetic markers of AD indicates that new tools and strategies are necessary to identify gene products useful as diagnostic tools.

AgingDiseaseImmunogeneticsDiagnostic toolsProteomicsPathogenesisApolipoproteins EAlzheimer DiseaseHumansMedicineOligonucleotide Array Sequence AnalysisInflammationAlzheimer’s disease cytokines immunogenetics inflammation proteomicsPolymorphism GeneticGeriatrics gerontologybusiness.industryDNARisk evaluationGene Expression RegulationPositron-Emission TomographyImmunologyCytokinesMicrogliaGeriatrics and GerontologybusinessBiomarkersAcute-Phase ProteinsAging Clinical and Experimental Research
researchProduct

Opiate-induced dopamine release is modulated by severity of alcohol dependence: an [(18)F]fallypride positron emission tomography study.

2011

Background Preclinical data implicate the reinforcing effects of alcohol to be mediated by interaction between the opioid and dopamine systems of the brain. Specifically, alcohol-induced release of β-endorphins stimulates μ-opioid receptors (MORs), which is believed to cause dopamine release in the brain reward system. Individual differences in opioid or dopamine neurotransmission have been suggested to be responsible for enhanced liability to abuse alcohol. In the present study, a single dose of the MOR agonist remifentanil was administered in detoxified alcohol-dependent patients and healthy control subjects to mimic the β-endorphin-releasing properties of ethanol and to assess the effect…

AgonistAdultMaleFluorine RadioisotopesPyrrolidinesmedicine.drug_classDopamineReceptors Opioid muPharmacologySeverity of Illness IndexRemifentanilRadioligand AssayDopamine receptor D1PiperidinesDopamine receptor D3DopaminemedicineLimbic SystemHumansBiological PsychiatryReceptors Dopamine D2PutamenFunctional NeuroimagingVentral striatumAlcohol dependenceMiddle AgedAnalgesics OpioidBehavior AddictiveAlcoholismmedicine.anatomical_structurenervous systemFallypridePositron-Emission TomographyBenzamidesPsychologymedicine.drugBiological psychiatry
researchProduct

Synthesis and evaluation of zirconium-89 labelled and long-lived GLP-1 receptor agonists for PET imaging

2020

Contains fulltext : 220838.pdf (Publisher’s version ) (Open Access) INTRODUCTION: Lately, zirconium-89 has shown great promise as a radionuclide for PET applications of long circulating biomolecules. Here, the design and synthesis of protracted and long-lived GLP-1 receptor agonists conjugated to desferrioxamine and labelled with zirconium-89 is presented with the purpose of studying their in vivo distribution by PET imaging. The labelled conjugates were evaluated and compared to a non-labelled GLP-1 receptor agonist in both in vitro and in vivo assays to certify that the modification did not significantly alter the peptides' structure or function. Finally, the zirconium-89 labelled peptide…

AgonistCancer ResearchBiodistributionmedicine.drug_class[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/ImagingPeptide[CHIM.THER]Chemical Sciences/Medicinal Chemistry[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineChemistry Techniques SyntheticPharmacologyRare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9]Glucagon-Like Peptide-1 Receptor030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineIn vivomedicineRadiology Nuclear Medicine and imagingTissue DistributionAmino Acid SequenceReceptorGlucagon-like peptide 1 receptorchemistry.chemical_classificationRadioisotopesRadiochemistryChemistryIn vitro toxicology030220 oncology & carcinogenesisDrug DesignIsotope LabelingPositron-Emission Tomography[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologyMolecular MedicineZirconiumPeptidesNanomedicine Radboud Institute for Molecular Life Sciences [Radboudumc 19]Ex vivoHalf-Life
researchProduct

Synthesis and Characterization of a Novel Series of Agonist Compounds as Potential Radiopharmaceuticals for Imaging Dopamine D-2/3 Receptors in Their…

2014

Imaging of dopamine D2/3 receptors (D2/3R) can shed light on the nature of several neuropsychiatric disorders in which dysregulation of D2/3R signaling is involved. Agonist D2/3 tracers for PET/SPECT imaging are considered to be superior to antagonists because they are more sensitive to dopamine concentrations and may selectively label the high-affinity receptor state. Carbon-11-labeled D2/3R agonists have been developed, but these short-lived tracers can be used only in centers with a cyclotron. Here, we report the development of a series of novel D2R agonist compounds based on the 2-aminomethylchromane (AMC) scaffold that provides ample opportunities for the introduction of longer-lived […

AgonistD-3 RECEPTORPHARMACOPHOREChemistrymedicine.drug_classDERIVATIVESPharmacologyIN-VIVO ACTIVITYHUMAN BRAINRadioligand AssayANTERIOR-PITUITARYPOSITRON-EMISSION-TOMOGRAPHYENDOGENOUS DOPAMINEIn vivoDopamineSpect imagingDopamine receptor D2Drug DiscoveryLIGAND-BINDINGmedicineMolecular MedicineReceptorAGENTSEndogenous agonistmedicine.drugJournal of Medicinal Chemistry
researchProduct

Die nächste Generation „atypischer” Antipsychotika: Der Beitrag der Positronenemissionstomographie

2003

Almost fifteen years of research with Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) have led to a profound understanding of the relationships between antipsychotic doses and plasma levels on the one hand and occupancy of (striatal) D 2 -like dopamine receptors on the other hand as well as with the associated clinical effects and side effects. Furthermore, with the development of clinically atypical" antipsychotics PET studies helped to generate hypotheses regarding the essential pharmacological properties of this heterogeneous class of drugs. Possible mechanisms of action include combined D 2 -/5-HT 2 antagonism, preferential mesolimbic binding, a…

Agonistmedicine.medical_specialtymedicine.diagnostic_testmedicine.drug_classmedicine.medical_treatmentSingle-photon emission computed tomographyPsychiatry and Mental healthEndocrinologyNeurologyMechanism of actionPositron emission tomographyDopamine receptorIn vivoInternal medicinemedicineAripiprazoleNeurology (clinical)medicine.symptomPsychologyAntipsychoticmedicine.drugFortschritte der Neurologie · Psychiatrie
researchProduct